SGLT2 inhibitors and dulaglutide are associated with comparable risk for dementia; however, it is uncertain whether these findings generalize to newer GLP-1 RAs.
In patients with type 2 diabetes, GLP-1 receptor agonists and SGLT2 inhibitors have similar kidney and cardiovascular outcomes. Similar kidney and cardiovascular outcomes are found with ...
New research analyzing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations. Cardiovascular disease is the ...